EP4 receptor antagonists
Compounds of formula (I): wherein: R is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NR, where R1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NR-, where R is selected from H, and optionally subs...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DAVID EDWARD CLARK CHRISTOPER GREGORY NEWTON NEIL VICTOR HARRIS ALEXANDER WILLIAM OXFORD GEORGE HYND ROBERT ALEXANDER COLEMAN RICHARD JON DAVIS GARRY FENTON KENNETH LYLE CLARK JONATHAN MARK SUTTON KEITH ALFRED JAMES STUTTLE |
| description | Compounds of formula (I): wherein: R is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NR, where R1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NR-, where R is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRR, where R and R are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2004207675BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2004207675BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2004207675BB23</originalsourceid><addsrcrecordid>eNrjZJBwDTBRKEpNTi0oyS9SSMwrSUzPz8ssLinmYWBNS8wpTuWF0twMKm6uIc4euqkF-fGpxQWJyal5qSXxjqFGBgYmRgbmZuamTk5GxkQqAwCnyiNz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>EP4 receptor antagonists</title><source>esp@cenet</source><creator>DAVID EDWARD CLARK ; CHRISTOPER GREGORY NEWTON ; NEIL VICTOR HARRIS ; ALEXANDER WILLIAM OXFORD ; GEORGE HYND ; ROBERT ALEXANDER COLEMAN ; RICHARD JON DAVIS ; GARRY FENTON ; KENNETH LYLE CLARK ; JONATHAN MARK SUTTON ; KEITH ALFRED JAMES STUTTLE</creator><creatorcontrib>DAVID EDWARD CLARK ; CHRISTOPER GREGORY NEWTON ; NEIL VICTOR HARRIS ; ALEXANDER WILLIAM OXFORD ; GEORGE HYND ; ROBERT ALEXANDER COLEMAN ; RICHARD JON DAVIS ; GARRY FENTON ; KENNETH LYLE CLARK ; JONATHAN MARK SUTTON ; KEITH ALFRED JAMES STUTTLE</creatorcontrib><description>Compounds of formula (I): wherein: R is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NR, where R1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NR-, where R is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRR, where R and R are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100520&DB=EPODOC&CC=AU&NR=2004207675B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100520&DB=EPODOC&CC=AU&NR=2004207675B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DAVID EDWARD CLARK</creatorcontrib><creatorcontrib>CHRISTOPER GREGORY NEWTON</creatorcontrib><creatorcontrib>NEIL VICTOR HARRIS</creatorcontrib><creatorcontrib>ALEXANDER WILLIAM OXFORD</creatorcontrib><creatorcontrib>GEORGE HYND</creatorcontrib><creatorcontrib>ROBERT ALEXANDER COLEMAN</creatorcontrib><creatorcontrib>RICHARD JON DAVIS</creatorcontrib><creatorcontrib>GARRY FENTON</creatorcontrib><creatorcontrib>KENNETH LYLE CLARK</creatorcontrib><creatorcontrib>JONATHAN MARK SUTTON</creatorcontrib><creatorcontrib>KEITH ALFRED JAMES STUTTLE</creatorcontrib><title>EP4 receptor antagonists</title><description>Compounds of formula (I): wherein: R is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NR, where R1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NR-, where R is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRR, where R and R are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJBwDTBRKEpNTi0oyS9SSMwrSUzPz8ssLinmYWBNS8wpTuWF0twMKm6uIc4euqkF-fGpxQWJyal5qSXxjqFGBgYmRgbmZuamTk5GxkQqAwCnyiNz</recordid><startdate>20100520</startdate><enddate>20100520</enddate><creator>DAVID EDWARD CLARK</creator><creator>CHRISTOPER GREGORY NEWTON</creator><creator>NEIL VICTOR HARRIS</creator><creator>ALEXANDER WILLIAM OXFORD</creator><creator>GEORGE HYND</creator><creator>ROBERT ALEXANDER COLEMAN</creator><creator>RICHARD JON DAVIS</creator><creator>GARRY FENTON</creator><creator>KENNETH LYLE CLARK</creator><creator>JONATHAN MARK SUTTON</creator><creator>KEITH ALFRED JAMES STUTTLE</creator><scope>EVB</scope></search><sort><creationdate>20100520</creationdate><title>EP4 receptor antagonists</title><author>DAVID EDWARD CLARK ; CHRISTOPER GREGORY NEWTON ; NEIL VICTOR HARRIS ; ALEXANDER WILLIAM OXFORD ; GEORGE HYND ; ROBERT ALEXANDER COLEMAN ; RICHARD JON DAVIS ; GARRY FENTON ; KENNETH LYLE CLARK ; JONATHAN MARK SUTTON ; KEITH ALFRED JAMES STUTTLE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2004207675BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2010</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DAVID EDWARD CLARK</creatorcontrib><creatorcontrib>CHRISTOPER GREGORY NEWTON</creatorcontrib><creatorcontrib>NEIL VICTOR HARRIS</creatorcontrib><creatorcontrib>ALEXANDER WILLIAM OXFORD</creatorcontrib><creatorcontrib>GEORGE HYND</creatorcontrib><creatorcontrib>ROBERT ALEXANDER COLEMAN</creatorcontrib><creatorcontrib>RICHARD JON DAVIS</creatorcontrib><creatorcontrib>GARRY FENTON</creatorcontrib><creatorcontrib>KENNETH LYLE CLARK</creatorcontrib><creatorcontrib>JONATHAN MARK SUTTON</creatorcontrib><creatorcontrib>KEITH ALFRED JAMES STUTTLE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DAVID EDWARD CLARK</au><au>CHRISTOPER GREGORY NEWTON</au><au>NEIL VICTOR HARRIS</au><au>ALEXANDER WILLIAM OXFORD</au><au>GEORGE HYND</au><au>ROBERT ALEXANDER COLEMAN</au><au>RICHARD JON DAVIS</au><au>GARRY FENTON</au><au>KENNETH LYLE CLARK</au><au>JONATHAN MARK SUTTON</au><au>KEITH ALFRED JAMES STUTTLE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>EP4 receptor antagonists</title><date>2010-05-20</date><risdate>2010</risdate><abstract>Compounds of formula (I): wherein: R is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NR, where R1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NR-, where R is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRR, where R and R are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2004207675BB2 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | EP4 receptor antagonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A29%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DAVID%20EDWARD%20CLARK&rft.date=2010-05-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2004207675BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |